Sellas Life Sciences Advances SLS009 Clinical Trial for AML
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Source: stocktwits
- Clinical Trial Update: SLS009 is being tested in combination with AbbVie and Bristol Myers Squibb's drugs, Venetoclax and Azacitidine, targeting 160 high-risk AML patients, with primary completion expected by late 2026, indicating potential positive implications for the company's future growth.
- Drug Mechanism: As a CDK9 inhibitor, SLS009 aims to block cancer cell survival and growth, with the current trial evaluating its efficacy in relapsed or refractory AML patients, potentially providing new treatment options in a competitive market.
- Investor Focus: While SLS009 serves as a new catalyst, investors remain focused on the Regal trial, which is nearing final survival analysis; the CEO emphasizes the importance of data, which could influence investor confidence and stock performance.
- Market Sentiment: SLS stock has surged 558% over the past year, with a recent 2% increase to $13.76, reflecting optimistic investor sentiment regarding the company's future, particularly in light of clinical trial advancements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.760
Low
7.00
Averages
7.25
High
7.50
Current: 13.760
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sellas Life Sciences Advances in Clinical Trials Amid Buyout Speculation
- Clinical Trial Progress: Sellas Life Sciences' GPS (galinpepimut-S) Phase 3 Regal trial in acute myeloid leukemia (AML) has reached 78 of the 80 events needed for final analysis, with a successful outcome potentially extending median overall survival from 8 months to 12.6 months, highlighting the company's therapeutic potential.
- Stock Price Volatility: Shares of Sellas fell 3% on Monday, marking the second consecutive day of declines, as the market remains highly focused on the upcoming Regal trial update, reflecting investor caution that could impact future financing and market confidence.
- Buyout Speculation: CEO Angelos Stergiou's upbeat LinkedIn post has sparked speculation about potential strategic partnerships and buyouts, although no explicit deal signals were given, this atmosphere may attract more investor interest and enhance the company's valuation.
- Market Value Growth: Sellas has seen its market value rise from approximately $73 million at the beginning of 2024 to over $1.5 billion by mid-2026, indicating strong performance in the capital markets, while ending Q1 with $107.1 million in cash bolsters its financial stability.
See More
Sellas Life Sciences Trial Update and Valuation Insights
- Trial Progress: Sellas Life Sciences' Regal trial has reached 78 events, just 2 shy of the 80 required for the final data readout, indicating potential implications for acute myeloid leukemia (AML) treatment, even as the stock has declined nearly 7% during this period.
- CEO Statement: CEO Stergiou rejected claims that the trial delay means longer survival for control group patients, emphasizing the lack of approved maintenance therapies and noting that existing treatments can cause severe side effects without significantly improving survival rates.
- Valuation Insights: Stergiou pointed out that valuing the company solely based on GPS's potential sales overlooks the broader value of its pipeline, particularly the SLS009 therapy being developed for multiple cancers, indicating that the strategic value of the company is not fully reflected in traditional valuation models.
- Market Sentiment: Despite the stock's decline, retail investor sentiment around SLS remains bullish, with expectations that the stock could “skyrocket” in the future, having gained nearly 190% so far this year.
See More
Sellas Life Sciences Advances SLS009 Clinical Trial for AML
- Clinical Trial Update: SLS009 is being tested in combination with AbbVie and Bristol Myers Squibb's drugs, Venetoclax and Azacitidine, targeting 160 high-risk AML patients, with primary completion expected by late 2026, indicating potential positive implications for the company's future growth.
- Drug Mechanism: As a CDK9 inhibitor, SLS009 aims to block cancer cell survival and growth, with the current trial evaluating its efficacy in relapsed or refractory AML patients, potentially providing new treatment options in a competitive market.
- Investor Focus: While SLS009 serves as a new catalyst, investors remain focused on the Regal trial, which is nearing final survival analysis; the CEO emphasizes the importance of data, which could influence investor confidence and stock performance.
- Market Sentiment: SLS stock has surged 558% over the past year, with a recent 2% increase to $13.76, reflecting optimistic investor sentiment regarding the company's future, particularly in light of clinical trial advancements.
See More
Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment
- Retail Trader Enthusiasm: In a poll of 3,400 users, Sellas Life Sciences (SLS) garnered 50% of the votes, significantly outpacing Ondas Holdings at 24% and ImmunityBio at 18%, indicating strong investor confidence in its future potential.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial in acute myeloid leukemia (AML) has reached 78 of the 80 events needed for final analysis, making the next two events critical catalysts that could drive stock price volatility.
- Acquisition Speculation: CEO Angelos Stergiou's optimistic remarks on social media and gratitude towards strategic partners have intensified market speculation regarding potential buyouts, likely attracting more investor interest.
- Significant Market Value Increase: Sellas' market value surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, reflecting heightened investor attention around the Regal readout, while the company ended Q1 with $107.1 million in cash, showcasing a robust financial position.
See More
MassMutual Acquires Small Stake in Sellas Life Sciences
- MassMutual Stake Acquisition: MassMutual Private Wealth & Trust disclosed ownership of 24 shares of Sellas Life Sciences (SLS) valued at $354.24 as of June 30, indicating growing interest in the company ahead of its acute myeloid leukemia (AML) trial results.
- Clinical Trial Progress: The Phase 3 Regal trial has reached 78 out of 80 required events, nearing a critical analysis point, and if successful, could extend the median overall survival of GPS treatment from 8 months to 12.6 months, significantly enhancing the company's competitive position in the market.
- Retail Investor Interest: The CEO's Independence Day post on social media sparked retail investor chatter about potential buyouts, reflecting heightened market interest in the company's future partnership opportunities, which has contributed to the stock's recent price surge.
- Shareholder Approval of Incentive Plan: Sellas recently received shareholder approval for a 20 million-share increase to its 2023 Equity Incentive Plan, with CEO Stergiou awarded 1.065 million restricted stock units, demonstrating the company's commitment to executive incentives and confidence in future growth.
See More
U.S. Bank Earnings Season Set to Begin
- Earnings Season Begins: Major U.S. banks are set to report Q2 earnings starting July 14, with market participants eager to gauge the strength of economic recovery, which could significantly influence investor confidence and market direction.
- Fed Minutes Release: The minutes from the Federal Reserve's June meeting will be released on Wednesday, with expectations that interest rates will remain steady at 3.5% to 3.75%, as investors look for guidance from new Chair Kevin Warsh on future policy, potentially impacting market expectations.
- Disappointing Jobs Data: U.S. payrolls increased by 57,000 in June, falling short of Wall Street expectations, which has lowered the odds of a July rate hike to 21.9%, highlighting the fragility of the economic recovery.
- Geopolitical Tensions: The funeral of Iran's former leader has tightened shipping flows through the Strait of Hormuz, potentially affecting global oil supply, as Brent crude prices fell by about 0.42% to $71.82 per barrel amid these developments.
See More
Sellas Life Sciences Advances in Clinical Trials Amid Buyout Speculation
- Clinical Trial Progress: Sellas Life Sciences' GPS (galinpepimut-S) Phase 3 Regal trial in acute myeloid leukemia (AML) has reached 78 of the 80 events needed for final analysis, with a successful outcome potentially extending median overall survival from 8 months to 12.6 months, highlighting the company's therapeutic potential.
- Stock Price Volatility: Shares of Sellas fell 3% on Monday, marking the second consecutive day of declines, as the market remains highly focused on the upcoming Regal trial update, reflecting investor caution that could impact future financing and market confidence.
- Buyout Speculation: CEO Angelos Stergiou's upbeat LinkedIn post has sparked speculation about potential strategic partnerships and buyouts, although no explicit deal signals were given, this atmosphere may attract more investor interest and enhance the company's valuation.
- Market Value Growth: Sellas has seen its market value rise from approximately $73 million at the beginning of 2024 to over $1.5 billion by mid-2026, indicating strong performance in the capital markets, while ending Q1 with $107.1 million in cash bolsters its financial stability.
See More
Sellas Life Sciences Trial Update and Valuation Insights
- Trial Progress: Sellas Life Sciences' Regal trial has reached 78 events, just 2 shy of the 80 required for the final data readout, indicating potential implications for acute myeloid leukemia (AML) treatment, even as the stock has declined nearly 7% during this period.
- CEO Statement: CEO Stergiou rejected claims that the trial delay means longer survival for control group patients, emphasizing the lack of approved maintenance therapies and noting that existing treatments can cause severe side effects without significantly improving survival rates.
- Valuation Insights: Stergiou pointed out that valuing the company solely based on GPS's potential sales overlooks the broader value of its pipeline, particularly the SLS009 therapy being developed for multiple cancers, indicating that the strategic value of the company is not fully reflected in traditional valuation models.
- Market Sentiment: Despite the stock's decline, retail investor sentiment around SLS remains bullish, with expectations that the stock could “skyrocket” in the future, having gained nearly 190% so far this year.
See More
Sellas Life Sciences Advances SLS009 Clinical Trial for AML
- Clinical Trial Update: SLS009 is being tested in combination with AbbVie and Bristol Myers Squibb's drugs, Venetoclax and Azacitidine, targeting 160 high-risk AML patients, with primary completion expected by late 2026, indicating potential positive implications for the company's future growth.
- Drug Mechanism: As a CDK9 inhibitor, SLS009 aims to block cancer cell survival and growth, with the current trial evaluating its efficacy in relapsed or refractory AML patients, potentially providing new treatment options in a competitive market.
- Investor Focus: While SLS009 serves as a new catalyst, investors remain focused on the Regal trial, which is nearing final survival analysis; the CEO emphasizes the importance of data, which could influence investor confidence and stock performance.
- Market Sentiment: SLS stock has surged 558% over the past year, with a recent 2% increase to $13.76, reflecting optimistic investor sentiment regarding the company's future, particularly in light of clinical trial advancements.
See More
Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment
- Retail Trader Enthusiasm: In a poll of 3,400 users, Sellas Life Sciences (SLS) garnered 50% of the votes, significantly outpacing Ondas Holdings at 24% and ImmunityBio at 18%, indicating strong investor confidence in its future potential.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial in acute myeloid leukemia (AML) has reached 78 of the 80 events needed for final analysis, making the next two events critical catalysts that could drive stock price volatility.
- Acquisition Speculation: CEO Angelos Stergiou's optimistic remarks on social media and gratitude towards strategic partners have intensified market speculation regarding potential buyouts, likely attracting more investor interest.
- Significant Market Value Increase: Sellas' market value surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, reflecting heightened investor attention around the Regal readout, while the company ended Q1 with $107.1 million in cash, showcasing a robust financial position.
See More
MassMutual Acquires Small Stake in Sellas Life Sciences
- MassMutual Stake Acquisition: MassMutual Private Wealth & Trust disclosed ownership of 24 shares of Sellas Life Sciences (SLS) valued at $354.24 as of June 30, indicating growing interest in the company ahead of its acute myeloid leukemia (AML) trial results.
- Clinical Trial Progress: The Phase 3 Regal trial has reached 78 out of 80 required events, nearing a critical analysis point, and if successful, could extend the median overall survival of GPS treatment from 8 months to 12.6 months, significantly enhancing the company's competitive position in the market.
- Retail Investor Interest: The CEO's Independence Day post on social media sparked retail investor chatter about potential buyouts, reflecting heightened market interest in the company's future partnership opportunities, which has contributed to the stock's recent price surge.
- Shareholder Approval of Incentive Plan: Sellas recently received shareholder approval for a 20 million-share increase to its 2023 Equity Incentive Plan, with CEO Stergiou awarded 1.065 million restricted stock units, demonstrating the company's commitment to executive incentives and confidence in future growth.
See More
U.S. Bank Earnings Season Set to Begin
- Earnings Season Begins: Major U.S. banks are set to report Q2 earnings starting July 14, with market participants eager to gauge the strength of economic recovery, which could significantly influence investor confidence and market direction.
- Fed Minutes Release: The minutes from the Federal Reserve's June meeting will be released on Wednesday, with expectations that interest rates will remain steady at 3.5% to 3.75%, as investors look for guidance from new Chair Kevin Warsh on future policy, potentially impacting market expectations.
- Disappointing Jobs Data: U.S. payrolls increased by 57,000 in June, falling short of Wall Street expectations, which has lowered the odds of a July rate hike to 21.9%, highlighting the fragility of the economic recovery.
- Geopolitical Tensions: The funeral of Iran's former leader has tightened shipping flows through the Strait of Hormuz, potentially affecting global oil supply, as Brent crude prices fell by about 0.42% to $71.82 per barrel amid these developments.
See More
